ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near San Francisco, CA, USA:

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...

Enrolling
Multiple Myeloma
Biological: bb2121
Drug: Talquetamab

Phase 2

Celgene
Celgene

San Francisco, California, United States and 25 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Bendamustine
Drug: CC-95266

Phase 1

Juno Therapeutics

San Francisco, California, United States and 9 other locations

CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: PHE885

Phase 2

Novartis
Novartis

Palo Alto, California, United States and 35 other locations

The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant...

Active, not recruiting
Multiple Myeloma
Biological: Ixazomib
Drug: Dexamethasone

Phase 2

The Washington University
The Washington University

San Francisco, California, United States and 9 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Palo Alto, California, United States and 59 other locations

1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: zevor-cel

Phase 1, Phase 2

CARsgen Therapeutics

San Francisco, California, United States and 12 other locations

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bisp...

Active, not recruiting
Multiple Myeloma
Drug: TNB-383B

Phase 1, Phase 2

TeneoOne

San Francisco, California, United States and 13 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Berkeley, California, United States and 211 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

San Francisco, California, United States and 126 other locations

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...

Enrolling
Multiple Myeloma
Biological: BMS-986393

Phase 2

Juno Therapeutics

San Francisco, California, United States and 46 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems